Andrew W. Roberts, MBBS, PhD

Metcalf Chair of Leukaemia Research
Royal Melbourne Hospital & Peter MacCallum Cancer Centre, Australia

NA

Poster(s):

• 1162 - Time-limited venetoclax-rituximab is effective for patients with Bruton tyrosine kinase exposed chronic lymphocytic leukaemia, but durable treatment-free remissions are uncommon